Inaktiver Wert

Durata Therapeutics Inc Aktie

Aktien

Schlusskurs Nasdaq Andere Börsenplätze
- ^USD	-

Durata Therapeutics : Actavis Receives FDA Approval for VIBERZI (eluxadoline) for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D) in Adults	01.06.15
Durata Therapeutics : Infectious Disease Experts, Scientists and Clinicians Join Forces on SHARE ID™ to Accelerate the Battle Against Antibiotic-resistant Infections	27.05.15
Durata Therapeutics : Actavis Confirms Generic Letairis® Patent Challenge	08.04.15
Durata Therapeutics : Actavis Announces Michael R. Gallagher and Peter J. McDonnell to Join Board of Directors	03.04.15
Durata Therapeutics : Actavis and Allergan Shareholders Approve Proposals Related to Actavis' Planned Acquisition of Allergan	12.03.15

Sektor

	% 1. Jan.	Kap.
IQVIA HOLDINGS INC.	+1,51 %	42,75 Mrd.
LONZA GROUP AG	+49,22 %	41,61 Mrd.
MODERNA, INC.	+8,57 %	41,34 Mrd.
CELLTRION, INC.	-12,36 %	26,59 Mrd.
ICON PUBLIC LIMITED COMPANY	+8,92 %	25,49 Mrd.
ALNYLAM PHARMACEUTICALS, INC.	-25,13 %	18,12 Mrd.
MEDPACE HOLDINGS, INC.	+29,17 %	12,24 Mrd.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3,12 %	11,76 Mrd.
UNITED THERAPEUTICS CORPORATION	+6,35 %	11 Mrd.